ArticleScientific reports2026
The diagnostic value of CDC20 for malignant pleural effusion of lung adenocarcinoma.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Lung adenocarcinoma (LUAD) is characterized by difficult early detection, rapid tumor progression and low surgical resection rate in the late stage. The common complication of patients with lung adenocarcinoma is malignant pleural effusion (MPE). Compared with lung biopsy, cytological examination of exfoliated pleural effusion is a less invasive operation. Therefore, there is an urgent need to discover new and effective cytological biomarkers for the exfoliation of LUAD pleural effusion. This work took the differentially expressed genes of LUAD tumors and adjacent tissues in the Gepia database as the entry point and screened out Cell division cycle protein 20 (CDC20) as a new biomarker for lung adenocarcinoma. The expression levels of CDC20, TTF-1 and NapsinA in 92 cases of lung adenocarcinoma and adjacent normal tissues were analyzed, and immunohistochemical detection was performed on paraffin specimens of pleural effusion from 30 cases of lung adenocarcinoma and 30 cases of non-neoplastic patients. Immunohistochemistry indicated that CDC20 was more expressed in LUAD tissues in the 92 observation groups and was related to tumor size, T classification, and pleural invasion. In this study, the results showed the expression of CDC20 was relatively consistent with that of TTF-1 and NapsinA in LUAD and malignant pleural effusion. This study reveals the potential diagnostic value of CDC20 in biopsy specimens of LUAD and pleural effusion. Our discovery is of great significance for the pathological diagnosis of pleural effusion cytology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.